Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Strontium ranelate (S12911), a strontium (II) salt of the ranelic acid, is a medication for osteoporosis. Studies indicate it can also slow the course of osteoarthritis of the knee. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in the treatment of severe osteoporosis.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
10 mg | 在庫あり | ¥ 7,500 | |||
25 mg | 在庫あり | ¥ 11,000 | |||
50 mg | 在庫あり | ¥ 18,500 | |||
100 mg | 在庫あり | ¥ 27,000 | |||
200 mg | 在庫あり | ¥ 45,500 | |||
500 mg | 在庫あり | ¥ 103,500 |
説明 | Strontium ranelate (S12911), a strontium (II) salt of the ranelic acid, is a medication for osteoporosis. Studies indicate it can also slow the course of osteoarthritis of the knee. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in the treatment of severe osteoporosis. |
ターゲット&IC50 | Ca2+ channel:0.5 mM |
別名 | Distrontium renelate, S12911 |
分子量 | 513.49 |
分子式 | C12H6N2O8S·2Sr |
CAS No. | 135459-87-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5.13 mg/ml (10 mM), Sonication is recommended.
H2O: Insoluble
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Strontium ranelate 135459-87-9 GPCR/G Protein Membrane transporter/Ion channel Metabolism CaSR Calcium Channel Calcium-sensing receptor Distrontium renelate S 12911 inhibit Inhibitor S-12911 S12911 inhibitor